Given that PTPN11 can modulate the RAS/MAPK signaling axis,18 further in vitro and clinical studies are needed to verify whether PTPN11mut combined with these mutations has a synergistic effect on the occurrence and development of AML. The gene discussed is PTPN11; the disease is acute myeloid leukemia.